1) Vitamin D For Chronic Pain - Pain Treatment Topics.org

VITAMIN D FOR 

CHRONIC PAIN 

According to a comprehensive review of the clinical 

research evidence, helping certain patients overcome 

chronic musculoskeletal pain and fatigue syndromes 

may be as simple, well tolerated, and inexpensive as 

a daily supplement of vitamin D. 

By Stewart B. Leavitt, MA, PhD 

Editor’s note: This article is adapted from the author’s peer-reviewed research report, Vitamin D— 

A Neglected ‘Analgesic’ for Chronic Musculoskeletal Pain, from Pain Treatment Topics. The 

full report, along with a special brochure for patients, is available at www.pain-topics.org/VitaminD. 

FIGURE 1. Vitamin D Metabolism 

Sunlight (UVB) 

Synthesis 

in Skin 

Cholecalciferol (D 3 ) 

25(OH)D 

1,25(OH) 2 D 

Metabolism 

in Liver 

25-hydroxyvitamin D 

(calcidiol) 

1,25-dihydroxyvitamin D 

(calcitriol – active) 

Biological Actions 

Certain Foods 

& Supplements 

Ergocalciferol (D 2 ) 

Cholecalciferol (D 3 ) 

Metabolism 

in Kidney 

Binding to 

Vitamin D Receptors 

Standing apart from the various other essential nutrients, 

vitamin D was spotlighted recently as having special therapeutic 

potential. This has important implications for the 

management of chronic musculoskeletal pain and fatigue 

syndromes. 

During this past June 2008, news-media headlines heralded 

recent clinical research that revealed benefits of vitamin D for 

preventing type 1 diabetes, 1 promoting survival from certain 

cancers, 2 and decreasing the risks of coronary heart disease. 3 

Overlooked, however, was the traditional role of vitamin D in 

promoting musculoskeletal health and the considerable evidence 

demonstrating advantages of vitamin D therapy in helping to 

alleviate chronic muscle, bone and joint aches, and pains of 

various types. 

Chronic pain—persisting more than 3 months—is a common 

problem leading patients to seek medical care. 4-7 In many cases, 

the causes are nonspecific, without evidence of injury, disease, or 

neurological or anatomical defect. 8,9 However, according to 

extensive clinical research examining adult patients of all ages, 

inadequate concentrations of vitamin D have been linked to nonspecific 

muscle, bone, or joint pain, muscle weakness or fatigue, 

fibromyalgia syndrome, rheumatic disorders, osteoarthritis, 

hyperesthesia, migraine headaches, and other chronic somatic 

complaints. It also has been implicated in the mood disturbances 

of chronic fatigue syndrome and seasonal affective disorder. 

Although further research would be helpful, current best 

evidence demonstrates that supplemental vitamin D can help 

many patients who have been unresponsive to other therapies 

for pain. Vitamin D therapy is easy for patients to self-administer, 

well-tolerated, and very economical. 

24 Practical PAIN MANAGEMENT, July/August 2008 

©2008 PPM Communications, Inc. Reprinted with permission.

Vitamin D for Chronic Pain 

It must be emphasized that vitamin D is not 

a pharmaceutical analgesic in the sense of 

fostering relatively immediate pain relief, and 

expectations along those lines would be unrealistic. 

Because Vitamin D supplementation 

addresses underlying processes, it may take 

months to facilitate pain relief, which can range 

from partial to complete. Furthermore, vitamin 

D supplementation is not proposed as a panacea 

or as a replacement for other pain treatment 

modalities that may benefit patient care. 

Vitamin D and ‘D-ficiency’ 

Pharmacology. Vitamin D comprises a group of 

fat-soluble micronutrients with two major forms: 

D 2 (ergocalciferol) and D 3 (cholecalciferol) 10,11 

(see Figure 1). Vitamin D 3 is synthesized in the 

skin via exposure of endogenous 7-dehydrocholesterol 

to direct ultraviolet B (UVB) radiation 

in sunlight and is also obtained to a small extent 

in the diet (see Table 1). In many countries, some 

foods are fortified with vitamin D 3 , which is the 

form used in most nutritional supplements. 14,20 

Vitamin D 2 , on the other hand, is found in 

relatively few foods or supplements. 14 

Following vitamin D synthesis in the skin or 

other intake, some of it is stored in adipose 

tissue, skeletal muscle, and many organs, 19 while 

a relatively small portion undergoes a two-stage 

process of metabolism (see Figure 1). First, D 2 

and/or D 3 are metabolized via hydroxylation in 

the liver to form 25-hydroxyvitamin D, abbreviated 

as 25(OH)D (also called calcidiol). 10,14,18,21,22 

This has minimal biological activity and serum 

concentrations of 25(OH)D accumulate gradually, 

plateauing at steady-state levels by about 40 

days 19,23,24 to 90 days. 25,26 

The 25(OH)D metabolite is converted primarily 

in the kidneys via further hydroxylation to 

1,25-dihydroxyvitamin D, abbreviated as 

1,25(OH) 2 D (also called calcitriol). It is the most 

important and biologically-active vitamin D 

metabolite with a short half-life of only 4 to 6 

hours 27 but can remain active for 3 to 5 days. 15,20 

A central role of vitamin D—via its active 

1,25(OH) 2 D metabolite—is to facilitate the 

absorption of calcium from the intestine and 

help maintain normal concentrations of this 

vital agent. Equally important, 1,25(OH) 2 D 

sustains a wide range of metabolic and physiologic 

functions throughout the body. 28 

Vitamin D actually is misclassified as a 

vitamin; it may be more appropriately considered 

a prohormone and its active 1,25(OH) 2 D 

metabolite—with its own receptors found in 

practically every human tissue—functions as a 

hormone. These vitamin D receptors, or VDRs, 

may affect the function of up to 1000 different 

genes 18,22,29,30,31 helping to control cell growth or 

differentiation. The VDRs themselves can differ 

Source 

TABLE 1: Sources of Vitamin D 

Vitamin D 2 and D 3 Sources 

Vitamin D Content 

Higher-Yield Natural Sources 

Exposure to sunlight, ultraviolet B radiation 

(0.5 minimal erythemal dose) † 3000–10,000 IU D 3 

Salmon fresh, wild (3.5 oz*) 600–1000 IU D 3 

Salmon fresh, farmed (3.5 oz) 100–250 IU D 3 

Salmon canned (3.5 oz) 300–600 IU D 3 

Herring, pickled (3.5 oz) 680 IU D 3 

Catfish, poached (3.5 oz) 500 IU D 3 

Sardines, canned (3.5 oz) 200–360 IU D 3 

Mackerel, canned (3.5 oz) 200–450 IU D 3 

Tuna, canned (3.6 oz) 200–360 IU D 3 

Cod liver oil (1 tsp / 0.17 oz) 400–1400 IU D 3 

Eastern oysters, steamed (3.5 oz) 642 IU D 3 

Shiitake mushrooms fresh (3.5 oz) 100 IU D 2 

Shiitake mushrooms sun-dried (3.5 oz) 1600 IU D 2 

Egg yolk, fresh 20–148 IU D 3 

Fortified Foods 

Fortified milk 60–100 IU/8 oz, usually D 3 

Fortified orange juice 60–100 IU/8 oz usually D 3 

Infant formulas 60–100 IU/8 oz usually D 3 

Fortified yogurts 100 IU/8 oz, usually D 3 

Fortified butter 50 IU/3.5 oz, usually D 3 

Fortified margarine 430 IU/3.5 oz, usually D 3 

Fortified cheeses 100 IU/3 oz, usually D 3 

Fortified breakfast cereals 60-100 IU/serving, usually D 3 

Food labels often express vitamin D content only as % of daily value, so it is usually 

unknown what the exact amount is in International Units (IU). 

Supplements 

Over The Counter/Internet 

‡ 

Multivitamin (including vitamin D) 400–800 IU vitamin D 2 or D 3 

Vitamin D (tablets, capsules) 

Various doses 400–50,000 IU 

(primarily D 3 ) 

Prescription/Pharmaceutical 

Vitamin D 2 (ergocalciferol) 

50,000 IU/capsule 

Drisdol ® , Calciferol ® , others(vitamin D 2 ) 

liquid supplements 

8000 IU/mL 

Rocaltrol ® , Calcigex ® , others (1,25[OH] 2 D) 

available outside US 

0.25-0.5 mcg capsules 

1 mcg/mL solution 

* 1 oz = 28.3 grams = 29.6 mL; 1 IU = 40 mcg (microgram) 

† A 0.5 minimal erythemal dose of UVB radiation would be absorbed after about 10-15 minutes 

of exposure of arms and legs to direct sunlight (depending on time of day, season, latitude, 

and skin sensitivity). Dark-skinned persons would require longer. 

‡ Ergocalciferol on product label signifies D 2 ; cholecalciferol signifies D 3 . 

References: Calcitriol 12 ; Ergocalciferol 13 ; Holick 14 ; Marcus 15 ; ODS 16 ; Singh 17 ; Tavera-Mendoza 

and White 18 ; and Vieth 19 25 

Practical PAIN MANAGEMENT, July/August 2008 



TABLE 2: DEFINING ADEQUATE 

25(OH)D CONCENTRATIONS 

25(OH)D Concentrations 

Major Metabolite of Vitamin D from D 2 or D 3 

Deficient 150 ng/mL 

In some literature 25(OH)D is expressed as nmol/L. 

The conversion formula is: 1 ng/mL = 2.5 nmol/L 

or 1 nmol/L = 0.4 ng/mL. 

References: Heaney 39 ; Heaney et al 42 ; Holick 14 ; Reginster et 

al 41 ; Tavera-Mendoza and White 18 ; Vieth 24 

in their genetic makeup (poly-morphism) 

and activity, which may account for 

varying individual responses to vitamin D 

therapy. 32,33 

The discovery of vitamin D receptors 

in many tissues besides intestine and 

bone—including heart, pancreas, breast, 

prostate, lymphocytes, and other 

tissues—implies that vitamin D supplementation 

might have applications for 

treating a number of disorders. These 

include autoimmune diseases, diabetes, 

cardiovascular disease, psoriasis, hypoparathyroidism, 

renal osteodystrophy, 

and possibly leukemia and cancers of the 

breast, prostate, or colon. 1-3,20,34-37 Research 

is ongoing in these areas. 

If vitamin D production or intake is 

diminished, reabsorption of vitamin D 

from tissue-storage reservoirs can 

sustain conversion to 25(OH)D and the 

1,25(OH) 2 D metabolite for several 

months. However, an abundant supply of 

vitamin D during certain times, such as 

from summer sun exposure, does not 

deter its complete depletion during 

periods of lean intake, such as during 

winter months. 19 

Numerous individual factors may affect 

the status of vitamin D and its metabolites 

in the body. Synthesis of vitamin D 3 in the 

skin in reaction to UVB exposure is a selflimiting 

reaction that achieves equilibrium 

within 20 to 25 minutes of exposure 

to strong sunlight in persons with white 

skin, with no net increase in D 3 production 

after that. 19 Persons with darker skin 

require longer sun exposure, but the total 

yield in D 3 is the same. Age is another 

limiting factor, and it is more difficult for 

older persons to acquire adequate vitamin 

D from UVB radiation. 21,28 

Adequate 25(OH)D Concentration. 

Most researchers agree that a minimum 

25(OH)D serum level of about 30 ng/mL 

or more is necessary for favorable calcium 

absorption and good health. 14,38-41 Optimal 

25(OH)D concentrations are considered 

to range from 30 ng/mL to 50 ng/mL (see 

Table 2). 20,35,36,42-44 

Most definitions of deficiency stress 

that circulating 25(OH)D concentrations 

of 100 ng/mL as possibly toxic, but this 

could be overly conservative and reported 

reference ranges are not always consistent 

from one laboratory to another. 

General Prevalence of “D-ficiency.” 

There is a growing consensus that vitamin 

D inadequacies in the general population—or 

what Holick [2004a] 112 has 

broadly labeled “D-ficiency”—are much 

more common and severe than might be 

imagined. This has been extensively 

studied and, according to the research 

evidence, it may be assumed in almost any 

clinical practice that at least 50% of 

patients will have 25(OH)D concentrations 

below 30 ng/mL, the lower limit of 

the optimal range. In many instances, the 

percentage of patients with vitamin D 

insufficiency will be much greater, and a 

significant proportion of them may have 

more serious deficiencies of






©2008 PPM Communications, Inc. Reprinted with permission. 

29


weakness. 20 Therefore, experts recommend that vitamin D 

deficiency and its potential for associated osteomalacia should 

be considered in the differential diagnosis of all patients with 

chronic musculoskeletal pain, muscle weakness or fatigue, 

fibromyalgia, or chronic fatigue syndrome. 27 

Table 3 summarizes 22 clinical investigations of vitamin D in 

patients with chronic musculoskeletal-related pain. These 

studies were conducted in various countries and included 

approximately 3,670 patients representing diverse populations 

and age groups. 

The percentage of patients with pain having inadequate 

vitamin D concentrations ranged from 48% to 100%, depending 

on patient selection and the definition of 25(OH)D 

“deficiency.” In most cases,


study of supplemental vitamin D versus broad-spectrum light 

therapy (phototherapy), which is often recommend for patients 

with SAD, vitamin D produced significant improvements in all 

outcome measures of depression, whereas the phototherapy 

group showed no significant changes. 97 

In a randomized, placebo-controlled study that included 

patients with clinical depression, those administered supplemental 

vitamin D had significantly enhanced mood and a reduction 

in negative-affect symptoms. 98 In similar investigations, 

more adequate vitamin D concentrations were associated with 

better physical, social, and mental functioning as measured by 

quality-of-life assessment instruments, 99 and improved scores on 

an assessment of well-being. 100 

In sum, while further research is needed, the potential benefits 

of vitamin D supplementation may be expanded from its role 

in supporting bone and muscle health to that of a complex 

hormonal system benefiting other conditions often associated 

with chronic pain. 31 

Assessing Vitamin D Status 

Clinical Indicators. From a clinical perspective, a number of 

factors may suggest that chronic musculoskeletal pain and 

related problems may be due to inadequate vitamin D intake. 

Researchers have stressed that the “gold standard” for a 

presumptive diagnosis of inadequate vitamin D is a review of 

patient history, lifestyle, and dietary habits that might pose risks 

for deficiency. 101 Along with this, indicators of defects in bone 

metabolism may include chronic muscle, bone, or joint pain, as 

well as persistent muscle weakness, fatigue, and possibly difficulty 

walking. 20,101,102 Radiological changes potentially associated 

with osteomalacia are seen only in advanced stages. 20,103 

Signs/symptoms of calcium deficiency (hypocalcemia) due to 

vitamin D deficiencies relate to neuromuscular irritability. Patients 

sometimes complain of paresthesias (numbness, tingling, prickling, 

or burning) in their lips, tongue, fingertips, and/or toes, 

along with fatigue and anxiety. Muscles can be painfully achy, 

progressing to cramps or spasms. 104-107 Lethargy, poor appetite, 

and mental confusion may be part of the syndrome. 104 

The diverse signs and symptoms may be erroneously attributed 

to other causes. Holick 14,44 and others 51,76 caution that osteomalacia 

due to vitamin D deficiency can be misdiagnosed as 

chronic fatigue syndrome, arthritis or rheumatic disease, depression, 

or fibromyalgia. 

Biochemical Markers. Laboratory assessments usually pertain 

to the measurement of biomarkers that could denote osteomalacic 

processes, including: 108 

• Serum 25(OH)D, total serum calcium (Ca), and phosphate 

(PO) are decreased to below normal ranges; 

• Parathyroid hormone (PTH) and total alkaline phosphatase 

(ALP) are elevated. 

It must be understood that there are limitations to the various 

laboratory assays in terms of their accuracy and/or helpfulness 

in making or confirming a diagnosis. Assessing ALP (a surrogate 

marker for bone turnover), PO, or Ca are not reliable 

predictors of inadequate 25(OH)D concentrations or underlying 

osteomalacic processes. 28,101 Up to 20% of patients with 

25(OH)D deficiency and elevated PTH may have normal Ca, 

PO, and ALP levels. 74,108 

It is generally believed that elevations of PTH may be a 

suitable biomarker of histological osteomalacia since, at the 

least, secondary hyperparathyroidism seeks to correct calcium 

deficits via bone resorption. A diagnosis of inadequate vitamin 

D with osteomalacic involvement to some extent could be 

presumed if PTH is elevated in association with low calcium 

levels, which also would serve to exclude patients with primary 

hyperparathyroidism due to other causes. 108 

Various assays for determining 25(OH)D concentrations in 

serum have relatively recently become available from commercial 

laboratories. 39,109 Circulating 25(OH)D reflects both D 2 plus 

D 3 intake, but not 1,25(OH) 2 D concentrations. Measuring 

1,25(OH) 2 D is not recommended because it can be a poor or 

misleading indicator of overall vitamin D status. 14,28,107 

There are some concerns about the validity and utility of 

25(OH)D assays, which also can be relatively expensive. 108 

Several testing methods are available and there can be significantly 

large differences in results from one laboratory to the 

next, as well as stark variations across types of assays. 21,39,46,110 Error 

rates can be high and the reference ranges reported may be 

confusing or unhelpful. These concerns should not completely 

deter testing for biomarkers related to vitamin D deficiency. 

Rather, informed healthcare providers need to consider test 

limitations and their objectives in using such measures, keeping 

in mind that patient-centered care focuses on individual needs 

rather than relying solely on laboratory values for guidance. 

While severe deficiencies in 25(OH)D and unambiguous clinical 

signs of osteomalacia relate most clearly to musculoskeletal 

pain, less severe vitamin D inadequacies are often unrecognized 

but nevertheless contributing sources of nociception in patients 

with chronic pain. 60 This has been proposed as a “subclinical” 

effect of vitamin D inadequacy, since subjective musculoskeletal 

pain or weakness develops prior to the emergence of more objective 

clinical indicators. 54,76,111 

Lotfi et al 54 proposed that in some persons even slight deficits 

of 25(OH)D can produce secondary hyperparathyroidism to a 

degree that manifests as musculoskeletal pain and/or weakness. 

Although vitamin D inadequacy may not be extreme enough to 

produce clinically diagnosable osteomalacia, it can still cause 

enough PTH elevation to generate increased bone turnover and 

loss, increased risk of microfractures, and pain or myalgia. 

As Holick 112 has suggested, either the level of 25(OH)D is 

adequate for the individual patient, or it is not. If it is inadequate, 

subclinical osteomalacia along with multiple forms of 

chronic pain and myopathy may emerge and the extent of the 

25(OH)D deficit in nanograms-per-milliliter may not matter – 

as long as the shortfall is corrected to the extent necessary. 

Vitamin D Therapy 

Vitamin D Intake in Healthy Persons. In 1997, the U.S. Institute 

of Medicine determined that there was insufficient data to 

specify a Recommended Daily Allowance (RDA) for vitamin D. 

Instead, the organization developed very conservative Adequate 

Intake (AI) values of 200 IU to 600 IU per day of vitamin D, 

based on an assumption that as people age they would need 

extra vitamin D supplementation 16,113 (see Table 4). 

According to the most recent 2005 Dietary Guidelines for 

Americans from the U.S. government, 114 and expert recommendations, 

14,18,24,42,58 healthy children and adults of any age should 

consume no less than 1000 IU/day of vitamin D 3 to reach and 

maintain minimum serum 25(OH)D concentrations of at least 




30 to 32 ng/mL. However, this may be inadequate. 

Clinical research trials have demonstrated that 1000 IU/day 

of vitamin D 3 produces only modest increases in 25(OH)D that 

can be inconsequential for achieving and maintaining optimal 

concentrations of 30 ng/mL or more in some persons. 26,29 Vieth 

and colleagues 26 demonstrated that 4000 IU/day D 3 could be 

safe and more effective in producing desired outcomes. Several 

general principles emerge from the accumulated research to 

date 19,21,23,25,26,39,46,100,115,116,117,118 : 

• Concentrations of 25(OH)D are not increased in direct 

proportion to the amount of supplementation increase. 

For example, tripling the D 3 dose—such as going from 600 

IU/day to 1800 IU/day—does not increase the concentration 

of 25(OH)D by threefold. 

• Any increase in 25(OH)D is also dependent on the concentration 

of this metabolite at the start of treatment. At 

equivalent vitamin D doses, patients with more severe 

baseline inadequacies will have larger, more rapid increases 

in 25(OH)D concentrations. 

• What might be considered large doses of vitamin D 3 by 

some practitioners do not produce proportionately large 

increases in 25(OH)D concentrations, depending on the 

amount of dose and duration of administration. For example, 

a single 50,000 IU dose of D 3 may produce a significantly 

smaller increase in 25(OH)D than 2000 IU given 

daily over time, and the increases from either of these 

could be modest. 

• However, it must be noted that continuous megadoses of 

vitamin D (eg, >50,000 IU) could produce robust, possibly 

toxic, increases in 25(OH)D concentrations over time. 

In everyday practice, exceptionally large daily doses of vitamin 

D would rarely be recommended to patients. Researchers have 

noted that raising 25(OH)D from 20 ng/mL to the more optimal 

30+ ng/mL range in otherwise healthy patients would require 

ongoing daily supplementation of only about 1300 IU 39 to 1700 

IU 119 of vitamin D 3 . However, it should be noted that the daily 

adequate intake of vitamin D for maintaining health is, in most 

cases, lower than the amount needed as therapy for patients 

with chronic pain. 

Putting “D” Into Clinical Practice. In patients with pain, 

researchers have examined daily vitamin D supplementation 

ranging from 600 IU to 50,000 IU, 19,27,116 as well as much larger 

amounts. Because vitamin D has a long half-life and can take 

several months to reach steady-state levels, one approach to 

supplementation has been to administer oral or intramuscular 

megadoses on an infrequent basis. For example, single doses of 

300,000 IU D 2 have been used in the expectation that they might 

suffice for many months. 120 Hathcock et al 121 and others 122 noted 

that amounts of vitamin D up to 100,000 IU would not be toxic 

if restricted to one administration every four months, or daily 

for a single period of four days. 

In one study of patients with chronic back pain, subjects were 

treated for 3 months with either 5000 IU/day or 10,000 IU/day 

of vitamin D 3 (heavier patients >50 kg received the larger 

dose), 74 There were no adverse effects reported, and pain 

symptoms were relieved in 95% of the patients. 

Despite the reported successes of larger-dose vitamin D 

supplementation, many healthcare providers may be uncomfortable 

with recommending such doses for their patients. And, 

TABLE 4. Recommended Vitamin D Intake in 

Healthy Persons 

1997 — Institute of Medicine 

200 IU/d – children and adults to age 50 years 

400 IU/d – men and women aged 50-70 years 

600 IU/d – those older than 70 years 

2005 — Dietary Guidelines for Americans 

1000 IU/d – children and adults 

Note: In some of the literature International Units are expressed 

as micrograms. The conversion formula is 1 IU = 0.025 mcg or 

1 mcg = 40 IU. 

unless pathways of vitamin D metabolism are impeded (eg, due 

to liver or renal disease or an interacting drug), such high doses 

could be unnecessary, at least as initial therapy. 

In patients with chronic pain, Gloth and colleagues 79 observed 

that symptom relief often can be achieved with relatively modest 

increases in 25(OH)D and 1,25(OH) 2 D concentrations. This is 

possibly because the vitamin D metabolites are being rapidly 

consumed at tissue sites and also becoming depleted in storage 

depots, so they cannot accumulate in needed quantities and so 

any added amount is beneficial. These researchers also 

suggested that pain syndromes may affect vitamin D receptors, 

causing them to become altered in function or increased in 

quantity (upregulated) and, thereby, physiologically requiring 

extra amounts of the 1,25(OH) 2 D hormone. 

A proposed conservative dosing protocol is outlined in Table 

5. This involves adding a daily supplement of 2000 IU of vitamin 

D 3 to a daily multivitamin regimen, bringing the total daily 

vitamin D 3 intake to 2400 IU to 2800 IU. This is a convenient 

supplement dose, since inexpensive 1000 IU D 3 tablets or 

capsules are readily available and some outlets are now stocking 

2000 IU/dose tablets. The daily cost of the supplement is 

typically US $ 0.10 or less. 

Vitamin D 3 products are preferred since they cost no more 

than D 2 and most research indicates that D 3 is more effective 

19,115,118,123 Vieth 19 has strongly urged that “all use of vitamin D 

for nutritional and clinical purposes should specify cholecalciferol, 

vitamin D 3 .” 

Vitamin D therapy would be contraindicated in patients with 

pre-existing excessive levels of calcium (hypercalcemia or hypercalcuria), 

and special caution might be advised in those prone 

to forming kidney stones or other calcifications. 12,13,121 Besides 

renal or hepatic dysfunction, intestinal malabsorption due to 

age, irritable bowel syndrome, Crohn’s disease, or celiac disease 

also may limit response to vitamin D therapy. 20,51,124 

Current therapies for chronic pain, started prior to initiating 

vitamin D 3 therapy, do not need to be discontinued; however, 

it must be accepted that it could be difficult to attribute improvements 

to one therapy over another. This would be confounded 

further if new therapies for pain are started during vitamin D 3 

supplementation and before enough time has elapsed to evaluate 

its effectiveness. 

If there are no improvements after several months of the 

proposed conservative vitamin D 3 dosing protocol, more time 

rather than increased doses may be necessary for vitamin D 3 



33


TABLE 5. Vitamin D Supplementation for 

Chronic Pain 

PROPOSED CONSERVATIVE DOSING PROTOCOL 

• In patients with chronic, nonspecific musculoskeletal 

pain and fatigue syndromes, it usually can be expected 

that vitamin D intake from combined sources is inadequate 

and concentrations of serum 25(OH)D are insufficient 

or deficient. 

• All patients should take a multivitamin to ensure at least 

minimal daily values of essential nutrients, including 

calcium and 400 IU to 800 IU of vitamin D. 

• Recommend a daily 2000 IU vitamin D 3 supplement, 

bringing total supplement intake to 2400 to 2800 IU/day 

(incl. from multivitamin). Extra calcium may not be necessary 

unless diet is insufficient and/or there are concerns 

about osteoporosis (e.g., in postmenopausal 

women or the elderly). 

• Monitor patient compliance and results for up to 3 

months. Other therapies for pain already in progress do 

not necessarily need to be discontinued. 

• If results are still lacking after 3 months, or persistent 

25(OH)D deficiency or osteomalacia are verified, consider 

a brief course of prescribed high-dose vitamin D 3 

with, or without, added calcium as appropriate, followed 

by ongoing supplementation as maintenance. 

therapy to effectively raise 25(OH)D concentrations, lower PTH 

levels, and/or saturate vitamin D receptors with the 1,25(OH) 2 D 

metabolite. In some cases, the patient might benefit from a 

course of high-dose vitamin D 3 supplementation followed by 

more conservative doses for ongoing maintenance. 

There is always the possibility that a particular chronic pain 

condition cannot be alleviated by vitamin D 3 supplementation 

alone. For example, there may be a previously undetected 

anatomic defect, disease, or other pathology that would benefit 

from another type of therapeutic intervention in addition to 

vitamin D therapy. 

At the doses recommended in Table 5, excessive accumulation 

of 25(OH)D or toxicity over time would not be expected 

and this supplementation might be continued indefinitely. It 

must be noted, however, that clinical investigations have largely 

observed subjects during months rather than years of ongoing 

supplementation, and long-term effects of vitamin D therapy 

on functions at the cellular level are still under investigation. 30 

If there are concerns, after a year or longer the supplement 

might be continued at a reduced dose; it can always be increased 

again if pain symptoms return. 

How Long Until Improvement In anecdotal case reports, 

vitamin D supplementation provided complete relief within a 

week in some patients having widespread, nonspecific pain that 

was unresponsive to analgesics, including opioids. 79 In other 

cases, pain and muscle weakness reportedly resolved “within 

weeks” of beginning supplementation. 72 

In one study, pain relief from neuralgia was achieved at 3 

months after beginning vitamin D supplementation. 91 In many 

cases, bone-related pain may require approximately 3 months 

of adequate vitamin D supplementation for its relief, 47,65 while 

muscle pain may need 6 months, and muscle weakness or fatigue 

may require even longer to resolve. 47,65,76 

Overall, Vasquez and colleagues 37 recommended that at least 

5 to 9 months should be allowed for fully assessing either the 

benefits or ineffectiveness of vitamin D supplementation. 

Likewise, Vieth et al 100 suggested that the greatest physiologic 

responses may occur after 6 months of supplementation. Therefore, 

the timeframe recommended in Table 5 – monitoring 

results for up to 3 months – should be considered a minimum 

period of watchful waiting. 

Complete pain relief would be easy for patients to detect, but 

in most cases this could be an unrealistic expectation. The 

evidence is suggestive of a potential range of improvements with 

vitamin D therapy, some more obvious than others. For example, 

instead of complete pain relief, patients may experience partial 

relief, reduced intensity or frequency of pain, less soreness or 

stiffness in muscles, increased stamina or strength, reductions 

in NSAID or opioid use, and/or improvements in mood or 

overall quality of life. These results are less spectacular than 

complete pain relief, but are still important and worthwhile 

outcomes to monitor. 

Vitamin D Safety Considerations 

The highly favorable safety profile of vitamin D is evidenced by 

its lack of significant adverse effects, even at relatively high 

doses, and the absence of harmful interactions with other drugs. 

While vitamin D is potentially toxic, reports of associated 

overdoses and deaths have been relatively rare. 

Tolerance & Toxicity. Excessive intake and accumulation of 

vitamin D is sometimes referred to as “hypervitaminosis D,” 

however this is poorly defined. Because a primary role of vitamin 

D is facilitating absorption of calcium from the intestine, the 

main signs/symptoms of vitamin D toxicity result from excessive 

serum calcium, or hypercalcemia (see Table 6). 

The rather diverse signs/symptoms of hypercalcemia in 

patients with pain may be difficult to attribute to vitamin D 

intoxication, since they might mimic those of opioid side effects, 

neuropathy, or other conditions. Paradoxically, some symptoms 

match those of hypocalcemia. In some cases, patients with serum 

25(OH)D at toxic levels can be clinically asymptomatic. 126 

Since full exposure to sunlight can provide the vitamin D 3 

equivalent of up to 20,000 IU/day, the human body can obviously 

tolerate and safely manage relatively large daily doses. Toxicity 

has not been reported from repetitive daily exposure to sunlight. 25 

Still, supplementation via commercially manufactured 

vitamin D products would circumvent natural mechanisms in 

human skin that prevent excess D 3 production and accumulation 

resulting from sun exposure. A Tolerable Upper Intake 

Level, or UL, for oral vitamin D 3 supplementation—which is 

the long-term dose expected to pose no risk of observed adverse 

effects—currently is defined in the United States as 1000 IU/day 

in infants up to 12 months of age and 2000 IU/day for all other 

ages. 16 However, many experts assert that the 2000 IU/day UL 

is far too low. 19,35-37,39,42 An extensive review by Hathcock et al, 121 

applying risk-assessment techniques, concluded that the UL for 

vitamin D consumption by adults actually could be 10,000 

IU/day of D 3 , without risks of hypercalcemia. 

However, the duration of high vitamin D intake may be the 




more critical factor. Taking 10,000 IU of D 3 daily for six months 

has been implicated as toxic, 22,132 whereas Holick [2007] 14 noted 

that this daily amount in adults can be well tolerated for five 

months. And, this 10,000 IU/day dose was used successfully and 

safely during three months in one study for relieving back pain. 74 

Vieth et al 100 demonstrated that 4000 IU of D 3 per day was well 

tolerated during 15 months of therapy. Concentrations of 

25(OH)D were increased to more optimal levels and parathyroid 

hormone was reduced, while calcium levels remained normal. 

Some researchers have proposed that long-term daily 

consumption of 40,000 IU of vitamin D would be needed to 

cause hypercalcemia. 18,19 The US Office of Dietary Supplements 

133 notes that hypercalcemia can result from 50,000 IU/day 

or more taken for an extended period of time. 

There have not been any reports in the literature of a single, 

one-time excessive dose of vitamin D (D 2 or D 3 ) being toxic or 

fatal in humans. However, a number of incident reports of 

vitamin D toxicity involving very high doses, and including 6 

fatalities, have appeared in the literature. In the incident 

reports, encompassing 77 cases of toxicity, amounts of vitamin 

D taken for periods ranging from days to years included daily 

doses from 160,000 IU up to an astounding 2.6 million 

IU. 125,126,128,129,130,131,134,135 The relatively few fatalities resulted from 

secondary causes during treatment for hypercalcemia. A 

common feature of all incidents was that victims were not 

knowingly or intentionally taking excessive amounts of vitamin 

D, and no one was taking vitamin D under practitioner supervision. 

In almost all cases, toxic overdoses could have been 

avoided with better quality control in product manufacture 

and/or education of patients in the proper use of supplements. 

As another measure of safety, consolidated data for 2006 were 

examined (the most recently reported year) from 61 poison 

control centers serving 300 million persons in the United 

States. 136 There were only 516 mentions of incidents involving 

vitamin D which, by comparison, were roughly one-fourth the 

number for vitamin C and merely 0.8% of all incidents involving 

vitamin products. Only 13% of all vitamin D cases required 

treatment in a healthcare facility, although adverse 

signs/symptoms were absent or minimal in almost all patients 

(92%). Only 5 of the victims had more pronounced 

signs/symptoms of vitamin D toxicity, but these were not life 

threatening and there were no serious adverse events reported. 

Vitamin D-Drug Interactions 

There have been relatively few mentions in the literature of 

vitamin D supplements interacting with other agents or medications, 

and these are summarized in Table 7. In most cases, the 

potency of vitamin D is reduced by the other drug and the 

vitamin dose can be increased to accommodate this. Conversely, 

very high doses of vitamin D should be avoided due to possible 

risks of hypercalcemia when taken with digitalis/digoxin or 

certain diuretics. 

Additionally, St. John’s wort, 27 excessive alcohol, 133 and tobacco 

smoking 138 have been reported to potentially reduce the effects 

of vitamin D. Mineral oil and stimulant laxatives decrease 

dietary calcium absorption and can influence hypocalcemia. 133 

Gastric bypass and other gastric or intestinal resection procedures 

have been associated with vitamin D insufficiency. 60,106 

It should be noted that not all patients would be affected by 

these interactions or effects, and vitamin D has not been noted 

TABLE 6. Signs/Symptoms of D Toxicity 

(Hypercalcemia) 

• abdominal pain 

• achy muscles/joints 

• anorexia 

• azotemia 

• calcifications 

• constipation 

• disorientation/confusion 

• fatigue/lethargy 

• fever/chills 

• GI upset 

• hypertension 

• muscle weakness 

• nausea 

• nervousness 

• polyuria 

• proteinuria 

• pruritus 

• excessive thirst 

• urinary casts 

• vomiting 

• weight loss 

References: Barrueto et al 125 ; Blank et al 126 ; Calcitriol 12 ; Carroll and 

Schade 127 ; Ergocalciferol 13 ; Johnson 20 ; Klontz and Acheson 128 ; Koutkia et 

al 129 ; Todd et al 130 ; Vieth et al 131 

to interfere harmfully with the actions of any medications. 

Therefore, none of the reported interactions or effects has been 

indicated in the literature as a contraindication for vitamin D 

supplementation. 

Conclusions 

Extensive clinical evidence and expert commentary supports the 

opinion that recommending adequate vitamin D intake for 

helping patients with chronic musculoskeletal pain and fatigue 

syndromes should be more widely recognized and acted upon. 

In many cases, contributing factors are nonspecific or undetermined. 

Even in cases where a specific etiology has been 

diagnosed, the potential for vitamin D deficit as a factor 

contributing to and/or prolonging the pain condition should 

not be ruled out. 

Further clinical research studies would be helpful. Vitamin D 

is not proposed as a “cure” for all chronic pain conditions or in 

all patients. Optimal clinical outcomes of vitamin D therapy 

might be best attained via multicomponent treatment plans 

addressing many facets of health and pain relief. Therefore, 

vitamin D is not suggested as a replacement for any other 

approaches to pain management. 

To start, a conservative total daily supplementation of 2400 

IU to 2800 IU of vitamin D 3 is proposed as potentially benefitting 

patients. Along with that, some patience is advised regarding 

expectations for improvements; it may require up to 9 

months before maximum effects are realized. In some cases, 

other factors or undetected conditions may be contributing to 

a chronic pain condition that vitamin D supplementation alone 

cannot ameliorate. 

In sum, for patients with chronic musculoskeletal pain and 

related symptoms, supplemental vitamin D has a highly favorable 

benefit to cost ratio, with minimal, if any, risks. In all likelihood, 

it would do no harm and probably could do much good.■ 

Acknowledgments 

The author wishes to acknowledge and thank the following 

expert reviewers of the full research report for their helpful 

comments and assistance: Bruce Hollis, PhD; Michael F. Holick, 

MD, PhD; Seth I. Kaufman, MD; Lee A. Kral, PharmD, BCPS; 

Paul W. Lofholm, PharmD, FACA; N. Lee Smith, MD; James D. 

Toombs, MD; Winnie Dawson, RN, BSN, MA. 



39


TABLE 7. Drugs Potentially Interacting with 

Vitamin D 

Potency of vitamin D is reduced. The vitamin dose 

can be increased to accommodate this. 

• antacids (aluminum- or magnesium-containing) 

• anticonvulsants (eg, carbamazepine) 

• antirejection meds (after organ transplant) 

• antiretrovirals(HIV/AIDS therapies) 

• barbiturates (eg, phenobarbital, phenytoin) 

• cholestyramine 

• colestipol 

• corticosteroids 

• glucocorticoids 

• hydroxychloroquine 

• rifampin 

Risk of hypercalcemia when taken concurrently. Very 

high doses of vitamin D should be avoided. 

• digitalis/digoxin 

• thiazide diuretics 

References: Bringhurst et al 137 ; Calcitriol 12 ; Ergocalciferol 13 ; 

Holick 14 ; Hollis et al 124 ; Marcus 15 ; Mascarenhas and Mobarhan 51 ; 

ODS 133 ; Turner et al 60 

Disclosure 

The author reports no involvement in the nutritional supplement 

industry or any other conflicts of interest. Covidien/ 

Mallinckrodt, St. Louis, MO, as a sponsor of Pain Treatment 

Topics, provided educational funding support for the research 

report on Vitamin D but had no role in its conception or development. 

The sponsor has no vested interests in the nutritional 

supplement industry and is not a manufacturer or distributor 

of vitamin products. 

Stewart B. Leavitt, MA, PhD, is the founding Publisher/Editor of Pain 

Treatment Topics and has more than 25 years of experience in healthcare 

education and medical communications serving numerous government 

agencies and other organizations. He was educated in biomedical 

communications at the University of Illinois at Chicago College of 

Medicine and then served as a Commissioned Officer in the US Public 

Health Service at the National Institutes of Health. He went on to earn 

Masters and Doctorate degrees specializing in health/medical research 

and education at Northwestern University, Evanston, Illinois. He is a 

member of the American Academy of Pain Management and a founding 

member of the International Association for Pain & Chemical 

Dependency. 

References 

1. Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet 

B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 

regions worldwide. Diabetologia. Online publication ahead of print, June 12, 2008. 

2. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin D levels and 

survival in patients with colorectal cancer. J Clin Oncol. 2008. 26(18):2984-2991. 

3. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of 

myocardial infarction in men. Arch Int Med. 2008. 168(11):1174-1180. 

4. APF (American Pain Foundation). Pain facts: overview of American pain surveys. 

2007. Available online at: http://www.painfoundation.org/page.aspfile=Newsroom/ 

PainSurveys.htm. Accessed 2/25/08. 

5. Nachemson A, Waddell G, Norlund A. Epidemiology of neck and back pain. In: 

Nachemson A, Jonsson E (eds) Neck and Back Pain: the Scientific Evidence of 

Causes, Diagnosis, and Treatment. Phila, PA: Williams & Wilkins; 2000: 165-188. 

6. NPF (National Pain Foundation). Harris Interactive Survey on Pain in America, Dec 

2007. Released in 2008. Avail at: http://www.nationalpainfoundation.org/ 

MyResearch/PainSurvey2008.asp. Accessed 2/25/08. 

7. Watkins EA, Wollan PC, Melton III J, Yawn PB. A population in pain: report from 

the Olmsted County Health Study. Pain Med. 2008. 9(2):166-174. 

8. Deyo RA. Diagnostic evaluation of LBP. Arch Intern Med. 2002. 162:1444-1448. 

9. Deyo RA, Weinstein JN. Low back pain. New Eng J Med. 2001. 344:363-370. 

10. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial. 2005. 

18:266-275. 

11. Lau AH, How PP. The role of the pharmacist in the identification and management 

of secondary hyperparathyroidism. US Pharmacist. 2007(Jul):62-70. Avail at: 

http://www.uspharmacist.com/index.asppage=ce/105514/default.htm. Accessed 

2/15/08. 

12. Calcitriol. Merck Manual [online]. 2007. Avail at: http://www.merck.com/ 

mmpe/lexicomp/calcitriol.html. Accessed 2/19/08. 

13. Ergocalciferol. Merck Manual [online]. 2007. Avail at: http://www.merck.com/ 

mmpe/lexicomp/ergocalciferol.html. Accessed 2/19/08. 

14. Holick MF. Vitamin D deficiency. N Engl J Med. 2007. 357(3):266-281. 

15. Marcus R. Agents affecting calcification and bone turnover: calcium, phosphate, 

parathyroid hormine, vitamin D, calcitonin, and other compounds. Chap 61. In: 

Hardman JG, Limbird LE, eds. Goodman & Gilman’s The Pharmacological Basis of 

Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1995. 

16. ODS (Office of Dietary Supplements; US National Institutes of Health). Dietary 

Supplement Fact Sheet: Vitamin D. Updated Feb 19, 2008. Avail at: http://dietarysupplements.info.nih.gov/ 

factsheets/vitamind.asp. Accessed 4/27/08 

17. Singh YN. Vitamin D. Part I: Are we getting enough US Pharm. 2004a. 10:66-72. 

Avail at: http://www.uspharmacist.com/index.aspshow=article&page= 

8_1352.htm. Accessed 4/29/08. 

18. Tavera-Mendoza LE, White JH. Cell defenses and the sunshine vitamin. Scientific 

American. Nov 2007. Avail at: http://www.sciam.com/article.cfm id=celldefenses-and-the-sunshine-vitamin. 

Accessed 3/1/08. 

19. Vieth R. The pharmacology of vitamin D, including fortification strategies. 

Chapter 61. In: Feldman D, Glorieux F, eds. Vitamin D. 2nd ed. Boston, MA: Elsevier 

Academic Press; 2005. Avail at: http://www.directms.org/pdf/VitDVieth/Vieth%20chapter 

%2061.pdf. Accessed 4/17/08. 

20. Johnson LE. Vitamin D. Merck Manual [online]. 2007. Avail at: 

http://www.merck.com/mmpe/ 

sec01/ch004/ch004k.htmlqt=vitamin%20D&alt=sh#tb004_6. Accessed 2/19/08. 

21. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: 

consequences for bone loss and fractures and therapeutic implications. Endocrine 

Rev. 2001. 22(4):477-501. 

22. Reginster J-Y. The high prevalence of inadequate serum vitamin D levels and 

implications for bone health. Curr Med Res Opin. 2005. 21(4):579-585. Avail at: 

http://www.medscape.com/viewarticle/504783_ print. Accessed 2/24/08. 

23. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin 

D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin 

Endocrinol Metab. 2008. 93(3):677-687. 

24. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and 

safety. Am J Clin Nutr. 1999. 69:842-856. 

25. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: 

implications for establishing a new effective dietary intake recommendation 

for vitamin D. J Nutr. 2005. 135:317-322. Available by search at: 

http://jn.nutrition.org/search.dtl. Accessed 4/2/08. 

26. Vieth R, Chan P-CR, MacFarlane GD. Efficacy and safety of vitamin D3 intake 

exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001:73: 288-294. 

Avail at: http://www.ajcn.org/cgi/content/full/73/2/288. 

27. Shinchuk L, Holick MF. Vitamin D and rehabilitation: improving functional 

outcomes. Nutr Clin Prac. 2007. 22(3):297-304. 

28. Holick MF. Vitamin D: the underappreciated D-lightful hormone that is important 

for skeletal and cellular health. Curr Opin Endocrinol Diabetes. 2002b;9:87-98. 

29. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem and health 

consequences. Am J Clin Nutr. 2008. 87(suppl):1080S-1086S. 

30. Marshall TG. Vitamin D discovery outpaces FDA decision making. Bioessays. 

2008. 30(2):173-182. 

31. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocrine 

Rev. 1992. 13(4):719-764. 

32. Kawaguchi Y, Kanamori M, Ishihara H, et al. The association of lumbar disc 

disease and vitamin-D receptor gene polymorphism. J Bone Joint Surg Am. 2002. 

84-A(11):2022-2028. 

33. Videman T, Gibbons LE, Battie MC, et al. The relative roles of intragenic 

polymorphisms of the vitamin D receptor gene in lumbar spine degeneration and 

bone density. Spine. 2001. 26(3):A1-A6. 

34. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate 

doses of solar ultraviolet-B radiation. Cancer. 2002. 94:1867-1875. 

35. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem. 2003a. 88:296- 

307. 

36. Holick MF. Vitamin D: photobiology, metabolism, mechanism of action, and clinical 

applications. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and 




Disorders of Mineral Metabolism. 5th ed. Washington, 

DC: American Society for Bone and Mineral Research. 

2003c:129-137. 

37. Vasquez A, Manso G, Cannell J. The clinical 

importance of vitamin D (cholecalciferol): a paradigm 

shirt with implications for all healthcare providers. Alternative 

Therapies. 2004. 10(5):28-36. Avail at: 

http://www.vitamindcouncil.com/PDFs/CME-clinicalImportanceVitD.pdf. 


38. Heaney RP. Vitamin D: how much do we need, and 

how much is too much Osteoporosis Int. 2000. 

11:553-555. 

39. Heaney RP. Functional indices of vitamin D status 

and ramifications of vitamin D deficiency. Am J Clin 

Nutr. 2004. 80(suppl):1706S-1709S. 

40. Heaney RP, Dowell MS, Hale CA, Bendich A. 

Calcium absorption varies within the reference range 

for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003b. 

22(2):142-146. 

41. Reginster J-Y, Frederick I, Deroisy R, et al. Parathyroid 

hormone plasma concentrations in response to 

low 25-OH vitamin D levels increase with age in elderly 

women. Osteoporosis Int. 1998. 8:390-392. 

42. Heaney RP, Davies KM, Chen TC, Holick MF, 

Barger-Lux MJ. Human serum 25-hydroxycholecalciferol 

response to extended oral dosing with cholecalciferol. 

Am J Clin Nutr. 2003a. 77:204-210. 

43. Holick MF. Sunlight and vitamin D: both good for 

cardiovascular health [editorial]. J Gen Intern Med. 

2002a. 17:733-735. 

44. Holick MF. Vitamin D deficiency: what a pain it is. 

Mayo Clin Proc. 2003b. 78:1457-1459. Avail at: 

http://www.mayoclinicproceedings.com/inside.aspAI 

D=464&UID. Accessed 2/18/08. 

45. Hickey L, Gordon CM. Vitamin D deficiency: new 

perspectives on an old disease. Curr Opin Endocrinol 

Diabetes. 2004. 11:18-25. 

46. AHRQ (Agency for Healthcare Research and 

Quality). Cranney A, Horsley T, O’Donnell S, et al. 

Effectiveness and safety of vitamin D in relation to bone 

health. Evidence report/technology assessment No. 

158 (prepared by the University of Ottawa Evidence- 

Based Practice Center [UO-EPC]). AHRQ publication 

07-E013; Aug 2007. Avail at: http://www.ahrq.gov/ 

downloads/pub/evidence/pdf/vitamind/vitad.pdf. 


47. Heath KM, Elovic EP. Vitamin D deficiency: implications 

in the rehabilitation setting. Am J Phys Med 

Rehabil. 2006. 85:916-923. 

48. Plotnikoff GA, Quigley JM. Prevalence of severe 

hypovitaminosis D in patients with persistent, nonspecific 

musculoskeletal pain. Mayo Clin Proc. 2003. 

78:1463-1470. 

49. Jacobs ET, Alberts DS, Foote JA, et al. Vitamin D 

insufficiency in southern Arizona. Am J Clin Nutr. 2008. 

87(3):608-613. 

50. Gostine ML, Davis FN. Vitamin D deficiencies in 

pain patients. Prac Pain Mgmt. 2006(July/Aug):16-19. 

51. Mascarenhas R, Mobarhan S. Hypovitaminosis D- 

induced pain. Nutrition Reviews. 2004. 62(9):354-359. 

52. Bhattoa HP, Bettembuk P, Ganacharya S. Prevalence 

and seasonal variation of hypovitaminosis D and 

its relationship to bone metabolism in community 

dwelling postmenopausal Hungarian women. Osteoporosis 

Int. 2004. 15:447-451. 

53. Hoogendijk VJG, Lips P, Dik MG, et al. Depression 

is associated with decreased 25-hydroxyvitamin D and 

increased parathyroid hormone in older adults. Arch 

Gen Psychiatry. 2008. 65(5):508-512. 

54. Lotfi A, Abdel-Nasser AM, Hamdy A, Omran AA, 

El-Rehany MA. Hypovitaminosis D in female patients 

with chronic low back pain. Clin Rheumatol. 2007. 

26:1895-1901. 

55. MacFarlane GD, Sackrison JL Jr, Body JJ, et al. 

Hypovitaminosis D in a normal, apparently healthy 

urban European population. J Steroid Biochem Mol 

Biol. 2004. 89-90(1-5):621-622. 

56. Nesby-O’Dell S, Scanlon KS, Cogswell ME, et al. 

Hypovitaminosis D prevalence and determinants 

among African American and white women of reproductive 

age: third National Health and Nutrition Examination 

Survey, 1988-1994. Am J Clin Nutr. 2002. 

76:187-192. 

57. Sullivan SS, Rosen CJ, Chen TC, Holick MF. 

Seasonal changes in serum 25(OH)D in adolescent 

girls in Maine [abstract]. J Bone Miner Res. 2003. 

18(suppl 2):S407. Abstract M470. 

58. Tangpricha V, Pearce EN, Chen TC, Holick MF. 

Vitamin D insufficiency among free-living healthy 

young adults. Am J Med. 2002. 112:659-662. 

59. Yew KS, DeMieri PJ. Disorders of bone mineral 

metabolism. Clin Fam Pract. 2002. 4:522–572. 

60. Turner MK, Hooten WM, Schmidt JE, et al. Prevalence 

and clinical correlates of vitamin D inadequacy 

among patients with chronic pain. Pain Med. 2008. 

online publication prior to print. 

61. Hooten WM, Turner MK, Schmidt JE. Prevalence 

and clinical correlates of vitamin D in adequacy among 

patients with chronic pain. American Society of 

Anesthesiologists 2007 annual meeting, San 

Francisco. Oct 13-17, 2007. Abstract A1380. 

62. Hicks GE, Shardell M, Miller RR, et al. Associations 

between vitamin D status and pain in older adults: the 

Invecchiare in Chianti Study. J Am Geriatr Soc. 2008. 

56(5):785-791. 

63. Armstrong DJ, Meenagh GK, Bickle I, et al. Vitamin 

D deficiency is associated with anxiety and depression 

in fibromyalgia [abstract]. Reported in: J Musculoskeletal 

Pain. 2007. 15(1):55. 

64. Kealing J. Study: Joint pain ebbs with vitamin D. 

San Antonio Breast Cancer Symposium, Dec 16, 2007 

– reported via LJWorld.com. Avail at: http://www2.lj 

world.com/news/2007/dec/16/study_joint_pain_ebbs_v 

itamin_d/. Accessed 5/2/08. 

65. de la Jara GDT, Pecoud A, Favrat B. Female 

asylum seekers with musculoskeletal pain: the importance 

of diagnosis and treatment of hypovitaminosis 

D. BMC Family Practice. 2006. 7(4). Avail at: 

http://www.biomedcentral.com/1471-2296/7/4. 

Accessed 3/8/08 

66. Benson J, Wilson A, Stocks N, Moulding N. 

Muscle pain as an indicator of vitamin D deficiency in 

an urban Australian Aboriginal population. Med J 

Australia. 2006. 185(2)76-77. Avail at: http://www.mja. 

com.au/public/issues/185_02_170706/ben10209_fm.ht 

ml. Access checked 3/3/08 

67. Helliwell PS, Ibrahim GH, Karim Z, Sokoll K, 

Johnson H. Unexplained musculoskeletal pain in 

people of South Asian ethnic group referred to a 

rheumatology clinic – relationship to biochemical 

osteomalacia, persistence over time and response to 

treatment with calcium and vitamin D. Clin Exp 

Rheumatol. 2006. 24(4):424-427. 

68. Erkal MZ, Wilde J, Bilgin Y, et al. High prevalence 

of vitamin D deficiencies, secondary to hyper-parathyroidism 

and generalized bone pain in Turkish 

immigrants in Germany: identification of risk factors. 

Osteoporosis Int. 2006. 17(8):1133-1140. 

69. Macfarlane GJ, Palmer B, Roy D, et al. An excess 

of widespread pain among South Asians: are low 

levels of vitamin D implicated Ann Rheum Dis. 2005. 

64(8):1217-1219. 

70. Baker K, Zhang YQ, Goggins J, et al. Hypovitaminosis 

D and its association with muscle strength, 

pain and physical function in knee osteoarthritis (OA): a 

30-month longitudinal, observational study. American 

College of Rheumatology meeting; San Antonio, TX; 

Oct 16-21, 2004. Abstract 1755. 

71. Haque U, Regan MJ, Nanda S. et al. Vitamin D: are 

we ignoring an important marker in patients with 

chronic musculoskeletal symptoms American College 

of Rheumatology meeting; San Antonio, TX; Oct 16- 

21, 2004. Abstract 694. 

72. van der Heyden JJ, Verrips A, ter Laak HJ, et al. 

Hypovitaminosis D-related myopathy in immigrant 

teenagers. Neuropediatrics. 2004. 35(5):290-292. 

73. Block SR. Vitamin D deficiency is not associated 

with nonspecific musculoskeletal pain syndromes 

including fibromyalgia [letter]. Mayo Clin Proc. 2004. 

79:1585-1591. Avail at: http://www.mayoclinicproceedings.com/inside.aspAID=2257&UID. 

Access 

checked 3/12/08. 

74. Al Faraj S, Al Mutairi K. Vitamin D deficiency and 

chronic low back pain in Saudi Arabia. Spine 2003. 

28:177-179. 

75. Huisman AM, White KP, Algra A, et al. Vitamin D 

levels in women with systematic lupus erythematosus 

and fibromyalgia. J Rheumatol. 2001. 28(11):2535- 

2539. 

76. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis 

D myopathy without biochemical signs of 

osteomalacic bone involvement. Calcif Tissue Int. 

2000b. 66:419-424. 

77. Prabhala A, Garg R, Dandona P. Severe myopathy 

associated with vitamin D deficiency in western New 

York. Arch Intern Med. 2000. 160(8):1199-1203. 

78. McAlindon TE, Felson DT, Zhang Y, et al. Relation 

of dietary intake and serum levels of vitamin D to 

progression of osteoarthritis of the knew among 

participants in the Framingham Study. Ann Int Med. 

1996. 125(5):353-359. Avail at: 

http://www.annals.org/cgi/ content/full/125/5/353. Accessed 

4/21/08 

79. Gloth FM 3rd, Lindsay JM, Zelesnick LB, 

Greenough WB 3rd. Can vitamin D deficiency produce 

an unusual pain syndrome Arch Intern Med. 1991. 

151:1662-1664. 

80. Boland R. Role of vitamin D in skeletal muscle 

function. Endocr Rev. 1986;7:434-438. 

81. Haddad JG, Walgate J, Min C, Hahn TJ. Vitamin D 

metabolite-binding proteins in human tissue. Biochem 

Biophys Acta. 1976;444:921-925. 

82. Schott G, Wills M. Muscle weakness in osteomalacia. 

Lancet. 1976;2:626-629. 

83. Simpson RU, Thomas GA, Arnold AJ. Identification 

of 1,25- dihydroxyvitamin D3 receptors and activities in 

muscle. J Biol Chem. 1985. 260:8882-8891. 

84. Pfeifer M, Begerow B, Minne HW, et al. Vitamin D 

status, trunk muscle strength, body sway, falls, and 

fractures among 237 postmenopausal women with 

osteoporosis. Exp Clin Endocrinol Diabetes. 2001. 

109:87-92. 

85. Bischoff HA, Stahelin HB, Dick W, et al. Effects of 

vitamin D and calcium supplementation on falls: a 

randomized controlled trial. J Bone Miner Res. 2003. 

18:343-351. 

86. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. 

Fracture prevention with vitamin D supplementation: a 

meta-analysis of randomized controlled trials. JAMA. 

2005. 293(18):2257-2264. 

87. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et 

al. Estimation of optimum serum concentrations of 25- 

hydroxyvitamin D for multiple health outcomes. Am J 

Clin Nutr. 2006. 84:18-28. 

88. Dukas L, Bischoff HA, Lindpainter LS, et al. 

Alfacalcidol reduces the number of fallers in a community-dwelling 

elderly population with a minimum 

calcium intake of more than 500 mg daily. J Am Geriatr 

Soc. 2004. 52:230-236. 

89. Sambrook PN, Chen JS, March LM, et al. Serum 

parathyroid hormone predicts time to fall independent 

of vitamin D status in a frail elderly population. J Clin 

Endocrinol Metab. 2004. 89:1572-1576. 

90. Boxer RS, Dauser RA, Walsh SJ, et al. The association 

between vitamin D and inflammation with the 6- 

minute walk and frailty in patients with heart failure. J 

Am Geriatr Soc. 2008. 56:454-461. 

91. Lee P, Chen R. Vitamin D as an analgesic for 

patients with type 2 diabetes and neuropathic pain. 

Arch Intern Med. 2008. 168(7):771-772. 

92. D’Ambrosio D, Cippitelli M, Cocciolo MG, et al. 

Inhibition of IL-12 production by 1,25-Dihydroxyvitamin 

D3. J Clin Invest. 1998. 101:252-262. 

93. Schleithoff SS, Zittermann A, Tenderich G, et al. 

Vitamin D supplementation improves cytokine profiles 

in patients with congestive heart failure: a double-blind 

randomized, placebo-controlled trial. Am J Clin Nutr. 

2006. 83:754-759. 

94. Van den Berghe, Van Roosbroeck D, Vanhove P, et 

al. Bone turnover in prolonged critical illness: effect of 



41


vitamin D. J Clin Endocr Metab. 2003. 88:4623-4632. 

95. Thys-Jacobs S. Alleviation of migraine with therapeutic 

vitamin D and calcium. Headache. 1994a. 

34(10)590-592. 

96. Thys-Jacobs S. Vitamin D and calcium in 

menstrual migraine. Headache. 1994b;34(9)544-546. 

97. Gloth FM 3rd, Alam W, Hollis B. Vitamin D vs 

broad spectrum phototherapy in the treatment of 

seasonal affective disorder. J Nutr Health Aging. 1999. 

3(1):5-7. 

98. Lansdowne AT, Provost SC. Vitamin D3 enhances 

mood in healthy subjects during winter. Psychopharmacology. 

1998. 135(4):319-323. 

99. Basaran S, Guzel R, Coskun-Benliday I, Guler- 

Uysal F. Vitamin D status: effects on quality of life in 

osteoporosis among Turkish women. Qaul Life Res. 

2007. 16(9):1491-1499. 

100. Vieth R, Kimball S, Hu A, Walfish PG. Randomized 

comparison of the effects of the vitamin D3 

adequate intake versus 100mcg (4000 IU) per day on 

biochemical responses and the wellbeing of patients. 

Nutrition J. 2004. 3:8. Avail at: http://www.nutritionj. 

com/content/pdf/1475-2891-3-8.pdf. Accessed 

5/14/08. 

101. Smith GR, Collinson PO, Kiely PD. Diagnosing 

hypovitaminosis D: serum measurements of calcium, 

phosphate, and alkaline phosphatase are unreliable, 

even in the presence of secondary hyper-parathyroidism. 

Rheumatol. 2005. 32(4):684-689. 

102. Nellen JFJB, Smulders YM, PH Jos Frissen, EH 

Slaats, J Silberbusch. Hypovitaminosis D in immigrant 

women: slow to be diagnosed. BMJ. 1996. 312:570-572. 

103. Peach H, Compston JE, Vedi S, Horton LWL. 

Value of plasma calcium, phosphate, and alkaline 

phosphate measurements in the diagnosis of histological 

osteomalacia. J Clin Pathol. 1982;35:625-630. 

Avail at: http://jcp.bmj.com/cgi/reprint/35/6/625. 


104. Cooper MS, Gittoes NJL. Diagnosis and management 

of hypocalcemia. BMJ. 2008. 336:1298-1302. 

105. Fitzpatrick L. Hypocalcemia: Diagnosis and Treatment 

– Chapter 7. 2002. Endotext.com. Avail at: 

http://www.endotext.org/parathyroid/parathyroid7/parat 

hyroid7.htm. Accessed 2/23/08. 

106. Lyman D. Undiagnosed vitamin D deficiency in 

the hospitalized patient. Am Fam Phys. 2005. 

71(2):299-304. Avail at: http://www.aafp.org/afp/ 

20050115/299.pdf. Accessed 4/30/08. 

107. Skugor M, Milas M. Hypocalemia. 2004. Cleveland 

Clinic; Avail at: http://www.clevelandclinicmeded. 

com/. Accessed 2/23/08. 

108. Peacey SR. Routine biochemistry in suspected 

vitamin D deficiency. JR Soc Med. 2004. 97:322-325. 

Avail at: http://www.jrsm.org/cgi/reprint/97/7/322. 


109. Zerwekh JE. Blood biomarkers of vitamin D 

status. Am J Clin Nutr. 2008. 87(suppl):1087S-1094S. 

110. Singh RJ. Are clinical laboratories prepared for 

accurate testing of 25-hydroxy vitamin D [letter]. Clin 

Chem. 2008. 54(1):221-223. 

111. Masood H, Narang AP, Bhat IA, Shah GN. Persistent 

limb pain and raised serum alkaline phosphatase 

the earliest markers to subclinical hypovitaminosis D in 

Kashmir [abstract]. Indian J Physiol Pharmacol. 1989. 

33(4):259-261. 

112. Holick MF. Vitamin D deficiency as a contributor 

to multiple forms of chronic pain – reply II [letter]. 

Mayo Clin Proc. 2004a;79:694-709. Avail at: 

http://www.mayoclinicproceedings.com/inside.aspAI 

D=2197&UID. Accessed 3/7/08. 

113. IOM (Institute of Medicine). Standing Committee 

on the Scientific Evaluation of Dietary Reference Intakes. 

Dietary Reference Intakes for Calcium, Phosphorus, 

Magnesium, Vitamin D, and Fluoride. Washington, DC: 

National Academy Press. 1997. 71-145. 

114. DHHS (US Department of Health and Human 

Services and US Dept of Agriculture). Dietary Guidelines 

for Americans, 2005. 6th ed. Washington, DC: 

US Government Printing Office. 2005(Jan). Avail at: 

http://www.health.gov/dietaryguidelines/dga2005/docu 

ment/. Accessed 5/18/08. 

115. Armas LAG, Hollis BW, Heaney RP. Vitamin D2 is 

much less effective that vitamin D3 in humans. J Clin 

Endocrinol Metab. 2004. 89(11):5387-5391. Avail at: 

http://jcem.endojournals.org/cgi/reprint/89/11/5387. 


116. Barger-Lux MJ, Heaney RP, Dowell S. Chen TC, 

Holick MF. Vitamin D and its major metabolites: serum 

levels after graded oral dosing in healthy men. Osteoporos 

Int. 1998. 8(3):222-230. 

117. Cranney A, Horsley T, O’Donnell S, et al. Effectiveness 

and safety of vitamin D in relation to bone 

health. Evid Rep Technol Assess. 2007. 158:1-235. 

118. Trang HM, Cole DEC, Rubin LA, et al. Evidence 

that vitamin D3 increases serum 25-hydroxyvitamin D 

more efficiently than does vitamin D2. Am J Clin Nutr. 

1998. 68:854-858. Avail at: http://www.ajcn.org/ 

cgi/reprint/68/4/854. Accessed 4/23/08. 

119. Vieth R, Bischoff-Ferrari H, Boucher BJ. The 

urgent need to recommend an intake of vitamin D that 

is effective. Am J Clin Nutr. 2007. 85:649-650. 

120. Smith H, Anderson F, Raphael P, et al. Effect of 

annual intramuscular vitamin D on fracture risk in 

elderly men and women – a population-based, 

randomized, double-blind, placebo-controlled trial. 

Rheumatology. 2007. 46(12):1852-1857. 

121. Hathcock JN, Shao A, Vieth R, Heaney R. Risk 

assessment for vitamin D. Am J Clin Nutr. 2007. 85:6- 

18. 

122. Trivedi DP, Doll R, Khaw KT. Effect of four monthly 

oral vitamin D3 (cholecalciferol) supplementation on 

fractures and mortality in men and women living in the 

community: randomized double blind controlled trial. 

Br Med J. 2003. 326:469. 

123. Romagnoli E, Mascia ML, Cipriani C, et al. Short 

and long term variations in serum calciotrophic 

hormones after a singe very large dose of ergocalciferol 

(vitamin D2) or cholecalciferol (vitamin D3) in the 

elderly. J Clin Endocrin Metab. 2008. online publication 

ahead of print; doi:10.1210/jc.2008-0350. 

124. Hollis BW, MacFarlane G, Valcour A. Clinical 

significance and assessment of 25 OH vitamin D. 

Burlington, NC: LabCorp; 2005. Avail at: http://www. 

labcorp.com/cme/pdf/Vitamin_D_Journal_Article.pdf. 


125. Barrueto F Jr, Wang-Flores HH, Howland MA, 

Hoffman RS, Nelson LS. Acute vitamin D intoxication 

in a child. Pediatrics. 2005. 116:e453-e456. 

126. Blank S, Scanlon KS, Sinks TH, Lett S, Falk H. An 

outbreak of hypervitaminosis D associated with the 

over fortification of milk from a home-delivery dairy. Am 

J Pub Health. 1995. 85(5):656-659. 

127. Carroll MF, Schade DS. A practical approach to 

hypercalcemia. Am Fam Physician. 2003. 67:1959- 

1966. Avail at: http://www.aafp.org/afp/20030501/ 

1959.html. Accessed 4/21/08. 

128. Klontz KC, Acheson DW. Dietary supplementinduced 

vitamin D intoxication [letter]. New Eng J Med. 

2007. 357:308-309. 

129. Koutkia P, Chen TC, Holick MF. Vitamin D intoxication 

associated with an over-the-counter sup-plement. 

New Engl J Med. 2001. 345(1):65-66. 

130. Todd MA, Bailey RR, Espiner EA, Lynn KL. 

Vitamin D2 for the treatment of chilblains – a cautionary 

tale. N Z Med J. 1987;100:465. 

131. Vieth R, Pinto TR, Reen BS, Wong MM. Vitamin D 

poisoning by table sugar. Lancet. 2002. 359:672. 

132. Jacobus CH, Holick MF, Shao Q, et al. Hypervitaminosis 

D associated with drinking milk. New Engl J 

Med. 1992;326:1173-1177. 

133. ODS (Office of Dietary Supplements; US National 

Institutes of Health). Dietary Supplement Fact Sheet: 

Calcium. Updated Sept 23, 2005. Avail at: 

http://dietary-supplements.info.nih.gov/ factsheets/ 

Calcium_pf.asp. Accessed 4/16/08 

134. Adams JS, Lee G. Gains in bone mineral density 

with resolution of vitamin D intoxication. Ann Int Med. 

1997. 127(3):203-206. 

135. Pettifor JM, Bikle DD, Cavaleros M. Serum levels 

of free 1,25-dihydroxyvitamin D in vitamin D toxicity. 

Ann Int Med. 1995. 122(7):511-513. 

136. Bronstein AC, Spyker DA, Cantilene Jr LR, et al. 

2006 Annual Report of the American Association of 

Poison Control Centers National Poison Data System 

(NPDS). Clinical Toxicology. 2007. 45(8):815-917. Avail 

at: http://www.aapcc.org/poison1.htm. Accessed 

2/22/08. 

137. Bringhurst RF, Bemay MB, Krune SM, Kronenberg 

HM. Bone and mineral metabolism in health and 

disease. In: Kasper DL, et al. eds. Harrison’s Principles 

of Internal Medicine. 16th Ed. New York: McGraw-Hill; 

2005: 2238-2249. 

138. Brot C, Jorgensen NR, Sorensen OH. The influence 

of smoking on vitamin D status and calcium 

metabolism. Eur J Clin Nutr. 1999. 53(12):920-926.

1) Vitamin D For Chronic Pain - Pain Treatment Topics.org

Create successful ePaper yourself

Delete template?

Save as template?